Capital 10X Interview Series | Mindset Pharma: Leaders in Next-Gen Psychedelics

Mindset Pharma: Leaders in Next-Gen Psychedelics

We had the pleasure of sitting down with James Lanthier, CEO of Mindset Pharma (CSE: MSET) (OTCQB: MSSTF).  We discussed some very exciting news – the company was recently approved by the MHRA to fast track their lead candidate MSP-1014 to Phase II clinical trials.  James also shared the story of their patents for non-hallucinogenic, non-tryptamine psychedelics and his thoughts on the rapid progress of the psychedelic movement.  He also shared Mindset Pharma’s edge – the buildout of a diverse library of intellectual property.

0:00 Fast tracking MSP-1014 to Phase II Clinical Trials
2:47 Mindset Pharma’s Edge
4:35 Diverse Portfolio of Drugs
6:31 Patents for Non-Hallucinogenic, Non-Tryptamine Compounds
9:06 The Controversy with Psychedelics without the High
11:12 The Rapid Pace of Psychedelics Advancement

Mindset Pharma is a market awareness client of Capital 10X.

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.


Please enter your comment!
Please enter your name here